Alnylam Pharmaceuticals, Inc
No trades
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0 USD
−278.16 M USD
2.25 B USD
130.94 M
About Alnylam Pharmaceuticals, Inc.
Sector
Industry
CEO
Yvonne L. Greenstreet
Website
Headquarters
Cambridge
Founded
2002
IPO date
May 28, 2004
Identifiers
3
ISIN US02043Q1076
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
ALNY5653584
Alnylam Pharmaceuticals, Inc. 1.0% 15-SEP-2027Yield to maturity
—
Maturity date
Sep 15, 2027
US2043QAC1
Alnylam Pharmaceuticals, Inc. 0.0% 15-SEP-2028Yield to maturity
—
Maturity date
Sep 15, 2028
See all 0HD2 bonds
Frequently Asked Questions
The current price of 0HD2 is 304 USD — it has decreased by −4.48% in the past 24 hours. Watch Alnylam Pharmaceuticals, Inc stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange Alnylam Pharmaceuticals, Inc stocks are traded under the ticker 0HD2.
0HD2 stock has fallen by −13.18% compared to the previous week, the month change is a −17.22% fall, over the last year Alnylam Pharmaceuticals, Inc has showed a 14.15% increase.
We've gathered analysts' opinions on Alnylam Pharmaceuticals, Inc future price: according to them, 0HD2 price has a max estimate of 580.00 USD and a min estimate of 351.00 USD. Watch 0HD2 chart and read a more detailed Alnylam Pharmaceuticals, Inc stock forecast: see what analysts think of Alnylam Pharmaceuticals, Inc and suggest that you do with its stocks.
0HD2 reached its all-time high on Oct 21, 2025 with the price of 495 USD, and its all-time low was 65 USD and was reached on Nov 15, 2018. View more price dynamics on 0HD2 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
0HD2 stock is 11.14% volatile and has beta coefficient of 0.99. Track Alnylam Pharmaceuticals, Inc stock price on the chart and check out the list of the most volatile stocks — is Alnylam Pharmaceuticals, Inc there?
Today Alnylam Pharmaceuticals, Inc has the market capitalization of 42.58 B, it has decreased by −9.04% over the last week.
Yes, you can track Alnylam Pharmaceuticals, Inc financials in yearly and quarterly reports right on TradingView.
Alnylam Pharmaceuticals, Inc is going to release the next earnings report on Apr 30, 2026. Keep track of upcoming events with our Earnings Calendar.
0HD2 earnings for the last quarter are 0.82 USD per share, whereas the estimation was 1.16 USD resulting in a −29.06% surprise. The estimated earnings for the next quarter are 1.48 USD per share. See more details about Alnylam Pharmaceuticals, Inc earnings.
Alnylam Pharmaceuticals, Inc revenue for the last quarter amounts to 1.10 B USD, despite the estimated figure of 1.15 B USD. In the next quarter, revenue is expected to reach 1.26 B USD.
0HD2 net income for the last quarter is 251.08 M USD, while the quarter before that showed −66.28 M USD of net income which accounts for 478.84% change. Track more Alnylam Pharmaceuticals, Inc financial stats to get the full picture.
No, 0HD2 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 12, 2026, the company has 2.23 K employees. See our rating of the largest employees — is Alnylam Pharmaceuticals, Inc on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Alnylam Pharmaceuticals, Inc EBITDA is 321.02 M USD, and current EBITDA margin is −5.35%. See more stats in Alnylam Pharmaceuticals, Inc financial statements.
Like other stocks, 0HD2 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Alnylam Pharmaceuticals, Inc stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Alnylam Pharmaceuticals, Inc technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Alnylam Pharmaceuticals, Inc stock shows the sell signal. See more of Alnylam Pharmaceuticals, Inc technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.